Cargando…

Emerging Therapeutic Strategies to Overcome Drug Resistance in Multiple Myeloma

SIMPLE SUMMARY: Multiple myeloma is a deadly blood cancer, but fortunately drug development has substantially prolonged the lifespan of patients to average more than a decade after diagnosis with optimal therapy. As a result, the population of patients living with multiple myeloma has grown consider...

Descripción completa

Detalles Bibliográficos
Autores principales:	Davis, Lorraine N., Sherbenou, Daniel W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8038312/ https://www.ncbi.nlm.nih.gov/pubmed/33918370 http://dx.doi.org/10.3390/cancers13071686

Ejemplares similares

309 MYC Inhibition Overcomes IMiD Resistance in Heterogeneous Multiple Myeloma Populations
por: Davis, Lorraine, et al.
Publicado: (2022)

MicroRNAs-Based Nano-Strategies as New Therapeutic Approach in Multiple Myeloma to Overcome Disease Progression and Drug Resistance
por: Desantis, Vanessa, et al.
Publicado: (2020)

Overcoming drug resistance by targeting protein homeostasis in multiple myeloma
por: Moscvin, Maria, et al.
Publicado: (2021)

Harnessing the T Cell to Treat Multiple Myeloma: Dawn of a New Therapeutic Paradigm
por: Keller, Alana L., et al.
Publicado: (2022)

Promising Anti-Mitochondrial Agents for Overcoming Acquired Drug Resistance in Multiple Myeloma
por: Innao, Vanessa, et al.
Publicado: (2021)

Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma
por: Muz, Barbara, et al.
Publicado: (2017)

Development of Antibiofilm Therapeutics Strategies to Overcome Antimicrobial Drug Resistance
por: Nadar, Sahaya, et al.
Publicado: (2022)

A drug repurposing strategy for overcoming human multiple myeloma resistance to standard-of-care treatment
por: Chroma, Katarina, et al.
Publicado: (2022)

Rational Targeting of Cdc42 Overcomes Drug Resistance of Multiple Myeloma
por: Nguyen, Phuong, et al.
Publicado: (2019)

Emerging Targeted Therapeutic Strategies to Overcome Imatinib Resistance of Gastrointestinal Stromal Tumors
por: Masucci, Maria Teresa, et al.
Publicado: (2023)

Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma
por: Issa, Mark E., et al.
Publicado: (2017)

Microenvironment drug resistance in multiple myeloma: emerging new players
por: Di Marzo, Lucia, et al.
Publicado: (2016)

Targeting an MDM2/MYC Axis to Overcome Drug Resistance in Multiple Myeloma
por: Faruq, Omar, et al.
Publicado: (2022)

Lenalidomide‐induced autoimmune enteropathy complicating treatment of multiple myeloma with concurrent systemic mastocytosis
por: Lakritz, Stephanie, et al.
Publicado: (2022)

Overcoming the Immunosuppressive Tumor Microenvironment in Multiple Myeloma
por: Uckun, Fatih M.
Publicado: (2021)

Targeting RFWD2 as an Effective Strategy to Inhibit Cellular Proliferation and Overcome Drug Resistance to Proteasome Inhibitor in Multiple Myeloma
por: Guo, Mengjie, et al.
Publicado: (2021)

Molecular mechanisms in multiple myeloma drug resistance
por: Nikesitch, Nicholas, et al.
Publicado: (2016)

Emerging drugs and combinations to treat multiple myeloma
por: Larocca, Alessandra, et al.
Publicado: (2017)

Hybrid Drugs—A Strategy for Overcoming Anticancer Drug Resistance?
por: Szumilak, Marta, et al.
Publicado: (2021)

Autophagy: A Potential Therapeutic Target to Tackle Drug Resistance in Multiple Myeloma
por: Bashiri, Hamed, et al.
Publicado: (2023)

SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma
por: Heynen, Guus J. J. E., et al.
Publicado: (2022)

Emerging strategies to overcome resistance to third-generation EGFR inhibitors
por: Shi, Kunyu, et al.
Publicado: (2022)

Artesunate overcomes drug resistance in multiple myeloma by inducing mitochondrial stress and non-caspase apoptosis
por: Papanikolaou, Xenofon, et al.
Publicado: (2014)

Toxicity management strategies for next-generation novel therapeutics in multiple myeloma
por: Steinbach, Mary, et al.
Publicado: (2022)

Current Landscape of Therapeutic Resistance in Lung Cancer and Promising Strategies to Overcome Resistance
por: Ashrafi, Adnin, et al.
Publicado: (2022)

Strategies to overcome drug resistance using SHP2 inhibitors
por: Liu, Meng, et al.
Publicado: (2021)

PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs
por: Herviou, Laurie, et al.
Publicado: (2018)

HDAC6-Selective Inhibitor Overcomes Bortezomib Resistance in Multiple Myeloma
por: Lee, Sang Wu, et al.
Publicado: (2021)

Dihydroartemisinin Induces Growth Arrest and Overcomes Dexamethasone Resistance in Multiple Myeloma
por: Chen, Ying, et al.
Publicado: (2020)

NANOMEDICINE: will it offer possibilities to overcome multiple drug resistance in cancer?
por: Friberg, Sten, et al.
Publicado: (2016)

Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update
por: Nijhof, Inger S., et al.
Publicado: (2017)

Chromosomal instability and acquired drug resistance in multiple myeloma
por: Wang, Wang, et al.
Publicado: (2017)

Role of micro-RNAs in drug resistance of multiple myeloma
por: Abdi, Jahangir, et al.
Publicado: (2016)

Multiple Myeloma: Available Therapies and Causes of Drug Resistance
por: Pinto, Vanessa, et al.
Publicado: (2020)

Drug resistance and minimal residual disease in multiple myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple Myeloma
por: Rasche, Leo, et al.
Publicado: (2019)

Role of Sphingolipids in Multiple Myeloma Progression, Drug Resistance, and Their Potential as Therapeutic Targets
por: Petrusca, Daniela N., et al.
Publicado: (2022)

Comparison of Strategies to Overcome Drug Resistance: Learning from Various Kingdoms
por: Ogawara, Hiroshi
Publicado: (2018)

The HGF/c-MET axis as a potential target to overcome survival signals and improve therapeutic efficacy in multiple myeloma
por: Giannoni, Paolo, et al.
Publicado: (2021)

Therapeutic Strategies for Overcoming Immunotherapy Resistance Mediated by Immunosuppressive Factors of the Glioblastoma Microenvironment
por: Miyazaki, Tsubasa, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6apc2li13jc6uoqnh3pq7hnt9m